- Pulse Biosciences, Inc. (PLSE, Financial) to announce Q1 2025 financial results on May 8, 2025.
- Conference call scheduled for 1:30 PM PT / 4:30 PM ET; webcast available online.
- The company focuses on Nanosecond Pulsed Field Ablation™ technology for medical applications.
Pulse Biosciences, Inc. (PLSE), a leader in bioelectric medicine, will release its first quarter 2025 financial results after the market closes on May 8, 2025. The company will conduct a conference call on the same day at 1:30 PM PT / 4:30 PM ET to discuss the results, which will be available live and as a recorded webcast on the Pulse Biosciences Investors website.
Pulse Biosciences specializes in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, a proprietary method that delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing surrounding noncellular tissues. This innovation holds promise for treating conditions like atrial fibrillation and has the potential to significantly impact various sectors within healthcare, particularly surgical soft tissue ablation.
With a market capitalization of $1.12 billion, Pulse Biosciences is a prominent player in the Medical Instruments & Supplies industry. The company is based in Hayward, California, and its stock (PLSE, Financial) is primarily held by insiders, owning 80.81%, with institutional investors holding 9.88% and a short interest of 3.67%.
For further information or to participate in the conference call, investors can dial 1-800-717-1738 or 1-646-307-1865. The webcast will provide an opportunity for stakeholders to engage with the company's latest developments and strategic direction.
